Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA
Enregistré dans:
Auteurs principaux: | Sam Gandy, David S. Knopman, Mary Sano |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMC
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f92c16d8aa1a4a8380db476dc21f17d2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Topical Insights Into the Post-Approval Controversies of Aducanumab
par: Dhiraj Kumar, et autres
Publié: (2021) -
Is Aducanumab for LMICs? Promises and Challenges
par: Illangage P. C. Gunawardena, et autres
Publié: (2021) -
Amyloid
Publié: (1994) -
Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
par: Devika Sirohi, et autres
Publié: (2017) -
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
par: Shuo Gu, et autres
Publié: (2018)